



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/047,434	10/25/2001	Rajendra Singh	SURR.74	2960
25871	7590	03/16/2004	EXAMINER	
SWANSON & BRATSCUN L.L.C. 1745 SHEA CENTER DRIVE SUITE 330 HIGHLANDS RANCH, CO 80129			CEPERLEY, MARY	
			ART UNIT	PAPER NUMBER
			1641	

DATE MAILED: 03/16/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 10/047,434	<b>Applicant(s)</b> SINGH ET AL.	
	<b>Examiner</b> Mary (Molly) E. Ceperley	<b>Art Unit</b> 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-26 is/are pending in the application.  
     4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-26 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
     a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

Art Unit: 1641

**1)** Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, drawn to protein mass tag (PMT) reagents comprised of an amino acid reactive moiety, classified based on the entire structure of the PMT including the particular type of "amino acid reactive moiety" (e.g. -COOH, -SH, -NH<sub>2</sub>, etc.).
- II. Claims 12-16, drawn to a plurality of protein mass tag reagents comprised of a recognition moiety and an amino acid reactive moiety, classified, for example in class 530, subclasses 391.3 and 391.5 when the recognition moiety is an antibody.
- III. Claims 17 and 18, drawn to a plurality of protein mass tag reagents comprised of a recognition moiety, an accessory moiety and an amino acid reactive moiety, classified, for example, in class 436, subclass 546 when the accessory moiety is fluorescent.
- IV. Claims 19-21, drawn to biotin-phenylglyoxal conjugates, classified in class 549, subclass 303.7.
- V. Claim 22, drawn to biotin-phenylamide conjugates which are further substituted on the phenyl ring with activated functional groups, classified in class 546, subclass 274.4 (pyridine ring containing).
- VI. Claims 23-26, drawn to a method of identifying proteins and a method of determining the relative amount of multiple proteins in at least two samples, classified in class 436, subclass 173.

**2)** The inventions are distinct, each from the other because of the following reasons:

**a)** Inventions I and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the compounds of I wherein the amino acid reactive moiety is

Art Unit: 1641

an amino group, for example, the amino group of 5-aminovaleric acid, could be used as a reactant to prepare N-benzyloxycarbonyl-5-aminopentanoic acid (Example 3 of U.S. 6,153,442).

**b)** Inventions I and II are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). In the instant case, the intermediate product of Invention I is deemed to be useful as an intermediate in the synthesis of a compound described in U.S. 6,153,442 (see the paragraph directly above) and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

**c)** Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have chemically different structures which result in different functions. For example, the compounds of Invention III which contain a fluorescent moiety possess a function not possessed by the compounds of Invention I which are required to have only a recognition moiety and an amino acid reactive moiety.

**d)** Inventions IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the compounds of the different inventions have different structures and functions. The phenylglyoxal compounds of Invention IV are reactive with arginine groups of a protein while the compounds of

Art Unit: 1641

Invention V contain no such phenylglyoxal functionality. The compounds of Inventions IV and V are also not related to Inventions I-III for the reason that there is no requirement that the compounds of Inventions I-III have the structures of the compounds of Inventions I-III.

**3)** Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, requiring divergent field of search and different patentability considerations, restriction for examination purposes as indicated is proper.

**4)** The claims of Inventions I-III and VI are generic to a plurality of disclosed patentably distinct species. For the election of any one of these inventions, applicants are required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. For the election of Invention I applicants must define the entire structure of the elected PMT compound; for Invention II, applicants must define the entire structure of the elected RM-PRM compound; for Invention III, applicants must define the entire structure of the elected RM-AM-PRM compound.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

**5)** Applicants are advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

**6)** Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named

Art Unit: 1641


inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

7) An inquiry of a general nature which is **not related to the prosecution on the merits** should be directed to Technology Center 1600 telephone number (571) 272-1600. The general fax number for the USPTO is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary (Molly) E. Ceperley whose telephone number is (571) 272-0813. The examiner can normally be reached from 8 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le, can be reached on (571) 272-0823.

March 15, 2004

  
Mary (Molly) E. Ceperley  
Primary Examiner  
Art Unit 1641